Company Overview
Kodiak Sciences Inc. operates as a clinical stage biopharmaceutical company dedicated to the research, development, and commercialization of therapeutics designed to treat retinal diseases. The company functions within the broader Healthcare sector, specifically the Biotechnology industry, where it focuses on advancing treatments for specific ophthalmological conditions. As of the latest data, the entity maintains a market capitalization of $1.33B and employs 123 individuals to support its extensive research and development initiatives. The company's annual revenue is not currently reported in standard financial statements, which indicates that its primary focus remains on capitalizing on future product commercialization rather than generating current sales volume. This lack of reported revenue alongside a significant market cap suggests that the company's valuation is driven by its pipeline potential and clinical trial progress rather than established operational cash flows.
Financial Health
The financial statements for Kodiak Sciences Inc. reflect a net income of $-217,336,000 and an EBITDA of $-204,704,000 over the trailing twelve-month period, while revenue is listed as N/A. The substantial gap between the reported revenue of N/A and the significant net loss of $-217,336,000 reveals a cost structure heavily weighted toward research, development, and clinical trial expenses typical of early-stage biopharmaceutical firms. Free cash flow stands at $-41,598,248, indicating that the company is burning cash to fund its operations and development programs rather than generating surplus liquidity for dividends or acquisitions. All three margin metrics—gross margin, operating margin, and profit margin—are reported as 0.0%, a figure that reflects the accounting treatment of a company with no revenue or N/A revenue where traditional margin calculations cannot be meaningfully expressed in percentages. Despite the losses, the company holds $72.04M in cash against $62.20M in debt, resulting in a debt-to-equity ratio of 262.54 which highlights a highly leveraged balance sheet relative to equity. The current ratio is 1.78, suggesting that the company possesses sufficient current assets to cover its short-term liabilities, though this liquidity is constrained by the need to sustain high burn rates. Furthermore, the return on equity is -207.9% and the return on assets is -47.2%, metrics that mathematically demonstrate the negative impact of current losses on shareholder value and asset efficiency rather than indicating operational effectiveness in a traditional sense.
Valuation Assessment
Valuation multiples for Kodiak Sciences Inc. present a complex picture given its financial stage, with a trailing P/E ratio listed as N/A due to negative earnings and a forward P/E of -5.86. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings potential that does not yet exist, as the negative forward multiple is a mathematical artifact of projected earnings remaining negative in the near term. The price-to-book ratio is 48.77, a figure that indicates the stock is trading at a substantial premium over its book value, reflecting high investor expectations for the success of its lead product candidate, tarcocimab tedromer. Alternative valuation metrics such as the price-to-sales ratio, which is N/A, and the EV/EBITDA of -5.60, further suggest that traditional valuation frameworks are less applicable to this clinical-stage asset until revenue generation begins. The stock has exhibited significant volatility, trading between a 52-week high of $31.18 and a 52-week low of $1.92. Without the specific current share price provided in the facts to calculate the exact percentage deviation, the wide range between the high and low demonstrates extreme price sensitivity common in small-cap biotechnology equities. Additionally, the beta is 2.69, indicating that the stock's price movements are expected to be highly volatile and amplify swings relative to the broader market index.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated significant revenue streams to calculate these rates. The absence of positive growth rates and N/A figures implies that the company is not currently in a phase of scaling operations or expanding sales, but rather in a phase of clinical development where revenue generation is not the primary metric. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that earnings are not being distributed to shareholders but are instead retained to fund ongoing research and development activities. This reinvestment strategy is standard for clinical-stage biopharmaceutical companies that prioritize bringing products to market over returning capital to investors. The overall growth and income profile is defined by a reliance on future commercialization success rather than current financial performance or income distribution.